- Home
- CHRS vs NRO Comparison
CHRS vs NRO Comparison
Compare CHRS & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NRO
- Stock Information
- Founded
- CHRS 2010
- NRO 2003
- Country
- CHRS United States
- NRO United States
- Employees
- CHRS N/A
- NRO N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NRO Finance/Investors Services
- Sector
- CHRS Health Care
- NRO Finance
- Exchange
- CHRS Nasdaq
- NRO Nasdaq
- Market Cap
- CHRS 84.2M
- NRO 156.7M
- IPO Year
- CHRS 2014
- NRO N/A
- Fundamental
- Price
- CHRS $0.83
- NRO $3.23
- Analyst Decision
- CHRS Buy
- NRO
- Analyst Count
- CHRS 3
- NRO 0
- Target Price
- CHRS $4.68
- NRO N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- NRO 239.4K
- Earning Date
- CHRS 08-07-2025
- NRO 01-01-0001
- Dividend Yield
- CHRS N/A
- NRO 11.41%
- EPS Growth
- CHRS N/A
- NRO N/A
- EPS
- CHRS N/A
- NRO N/A
- Revenue
- CHRS $272,251,000.00
- NRO N/A
- Revenue This Year
- CHRS N/A
- NRO N/A
- Revenue Next Year
- CHRS $106.56
- NRO N/A
- P/E Ratio
- CHRS N/A
- NRO N/A
- Revenue Growth
- CHRS 19.87
- NRO N/A
- 52 Week Low
- CHRS $0.66
- NRO $2.51
- 52 Week High
- CHRS $2.43
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- CHRS 56.33
- NRO 50.97
- Support Level
- CHRS $0.73
- NRO $3.19
- Resistance Level
- CHRS $0.82
- NRO $3.27
- Average True Range (ATR)
- CHRS 0.04
- NRO 0.04
- MACD
- CHRS 0.01
- NRO 0.00
- Stochastic Oscillator
- CHRS 99.23
- NRO 62.50
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").